1st August 2018
article written by
Cell Medica

Chris Nowers

Chris joined Cell Medica from the cancer immunotherapy company Kite Pharma (Kite), where he was Head of Europe and responsible for the full commercialisation of the CAR-T therapy axicabtagene ciloleucel. At Kite he built the European organisation from the ground up and, post the $12 Bn acquisition by Gilead Sciences in 2017, was subsequently responsible […]

Read Full Article
16th July 2015
article written by
admin

Karen Hodgkin

Karen has over 30 years of experience in planning and running clinical trials, which has been invaluable in the creation of Cell Medica’s highly-efficient clinical operations and regulatory function. After working as SVP, Clinical Operations, Karen has moved to become Cell Medica’s COO in September 2016. In the past, Karen has worked for Boehringer Ingelheim […]

Read Full Article
15th September 2017
article written by
Cell Medica

Dr Luis Borges

Luis has over 21 years of experience working in the discovery and development of novel therapies for cancer treatment. After earning his doctorate degree in Pathology at the University of Washington in Seattle, Luis began his drug development career at Immunex, where he gained significant experience in immunology and cancer immunotherapy. After the acquisition of […]

Read Full Article
5th February 2018
article written by
Cell Medica

Kevin Boyle

Kevin has over 20 years of diversified finance experience helping companies define and achieve strategic financial objectives.  He has broad international experience with both public and private companies and has raised over $2.0 billion in capital over his career. Before joining Cell Medica, Kevin served as Chief Financial Officer of FloWorks International and had held […]

Read Full Article